Analysis of the Framingham Heart Study experience between 1958 and 1970 showed a progressive increase in the rate of treatment and control of hypertension. With cross-sectional criteria to define diastolic hypertension, the treatment rate rose from 35% in 1958 through 1960 to 69% in 1968 through 1970 (p < .001), and the treatment rate for sustained hypertension rose from 55% in 1958 through 1960 to 85% in 1968 through 1970 (p < .001). Treated hypertensive subjects had higher pretreatment values of blood pressure but not of other cardiovascular risk factors than untreated hypertensive subjects. Treatment was more successful in controlling hypertension in later years (p <
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Heart Study during the period 1958 to 1970, immediately preceding the downturn in cardiovascular mortality. We describe secular trends in the rates of treatment and control of hypertension, factors that influence which subjects are treated, and the effects of treatment on other cardiovascular risk factors and on the overall risk of coronary heart disease.
Methods
The study cohort was a stratified random sample of the adult population of Framingham, Massachusetts. The subjects were first examined between 1949 and 1952, when they were 29 to 62 years of age, and have been examined biennially since that time. The cohort received all medical care from community practitioners, who were informed of findings at the study examinations. No recommendations for treatment were made to the subjects or their physicians, and no treatment was offered at the Heart Study.
Data on the use of antihypertensive agents was gathered by interview of the subjects, starting with the fourth examination between 1958 and 1960. Data from the fifth through tenth examinations were analyzed. Details regarding the study design, response, follow-up, definition of clinical variables, and examination procedures have been reported elsewhere.8-10 All blood pressures used were the second of three recorded at each examination.
Rates of treatment and control. Because individuals' blood pressures vary over time, we used two different sets of criteria to define the presence of hypertension: the cross-sectional criteria required hypertension at one examination only, while the sustained criteria required hypertension at two consecutive examinations.
Cross-sectional criteria. Hypertensive subjects were defined at each examination as those individuals who had diastolic blood pressure of 95 mm Hg or greater or who were on antihypertensive treatment.5 Rate of treatment was calculated with those on treatment as the numerator and all hypertensive subjects as the denominator. Systolic hypertension was defined as blood pressure of 160 mm Hg or greater.
Sustained criteria. We used data from two consecutive examinations to identify subjects with clearly established, sustained hypertension. An individual had sustained hypertension at the second of the two examinations if he or she met any of the following criteria: (1) treated at the second examination, (2) treated at the first examination and not treated at the second but having diastolic blood pressure of 95 mm Hg or greater at the second examination, and (3) not treated at either examination but having diastolic blood pressure of 95 mm Hg or greater at both. Treatment was ascertained at the second of the two consecutive examinations. Rate of treatment was defined as the number of treated hypertensive subjects divided by the number with sustained hypertension.
Rates of hypertension treatment were age-standardized by the direct method."' The group with cross-sectionally defined diastolic hypertension was the standard population. Subjects with missing values for the treatment variable were omitted from the analysis. Control of hypertension. The rate of control of hypertension was calculated at each examination, with treated subjects having diastolic blood pressure of 95 mm Hg or less as the numerator and all those on treatment as the denominator.
Clinical factors influencing selection of patients for treatment. We analyzed individuals at risk to be treated, defined as having a diastolic blood pressure of 95 mm Hg or greater and not already on treatment. Patients who met these criteria at the first of two consecutive examinations were classified as treated if they were taking antihypertensive agents at the second examination and as untreated if they were not. Clinical characteristics at the first examination were compared in the treated and untreated groups. Cardiovascular risk factors that were analyzed included age, sex, systolic and diastolic blood pressure, glucose level and glucose intolerance, serum cholesterol level, cigarette smoking, left ventricular hypertrophy on the resting electrocardiogram, and an overall predicted risk of coronary heart disease calculated from previously published'2 multiple logistic regression equations. The following variables were also examined: any abnormality on the resting electrocardiogram, including left ventricular hypertrophy; proteinuria; cardiomegaly on the chest radiograph; a summary variable that was defined as positive if any of these three abnormalities was present; preexisting coronary heart disease as defined by clinical or electrocardiographic evidence of angina pectoris or myocardial infarction'0; preexisting cardiovascular disease as defined by evidence of coronary heart disease, claudication, or cerebrovascular disease'0; and a second summary variable that was positive if any of these laboratory or clinical abnormalities was present.
A stepwise multiple logistic regression analysis was performed with treatment as the outcome variable and the clinical factors listed above as potential predictive variables. Data for all 544 treated subjects and for an equal number of randomly selected untreated hypertensive subjects, chosen from the groups at risk for treatment, were analyzed.
Changes in cardiovascular risk factors associated with treatment. To study changes in risk factors, including systolic blood pressure, diastolic blood pressure, serum cholesterol level, blood glucose, glucose intolerance, cigarette smoking, and left ventricular hypertrophy, hypertensive subjects were again studied at two consecutive examinations. The treated group comprised subjects with diastolic blood pressure of 95 mm Hg or greater who were not on treatment at the first of the two examinations and who were on treatment at the second examination. The untreated group consisted of subjects with diastolic blood pressure of 95 mm Hg or greater at both examinations who were not on treatment at either the first or second examination. Overall predicted risk of coronary heart disease, defined as clinical or electrocardiographic evidence of angina pectoris, myocardial infarction, sudden death, or non-sudden coronary heart disease death,'0 was calculated,'2 holding age constant as the age at the first examination. The changes in each risk factor and in overall predicted risk between the first and second examinations were compared in the treated and untreated groups.
Because the blood pressure level at the first examination was the most important correlate of whether a subject would be treated at the second examination, the distributions of blood pressure in the treated and untreated groups differed significantly. We therefore compared treated and untreated subjects across subgroups stratified according to systolic and diastolic blood pressure at the first examination, in intervals of 5 mm Hg for diastolic and 10 mm Hg for systolic blood pressure.
In the analyses of factors influencing which hypertensive subjects were on treatment and of the effects of treatment on cardiovascular risk factors, data from each examination were analyzed as statistically independent observations so that the total number of observations in the analysis was larger than the number of individual subjects in the study. This practice is consistent with previous analyses of the Framingham Heart Study experience. '2 Comparison to treatment trial data. The most suitable treatment trial for comparison to the Framingham experience is the Australian National Blood Pressure Study (ANBPS),'3' '4 since the ANBPS reported specific diagnostic end points based on an "on-treatment" analysis as well as an "intent to treat" analysis. End points in the ANBPS that were considered comparable to the end point of coronary heart disease at Framingham, and therefore included in the comparative analysis, included fatal myocardial infarction, nonfatal myocardial infarction, and other coronary heart disease. Data reported in the ANBPS as events per person-year (incidence rate, IR) were transformed into a probability of having a coronary heart disease event at 8 years (cumulative incidence) by the following formula'5: cumulative incidence = 1 -e (IR) (8 years)
A subset of the Framingham cohort was selected according to the same criteria used in the ANBPS. Patients were included if at the first examination they were free of coronary heart disease, were 30 to 69 years old, and had a diastolic blood pressure of 95 to 109 mm Hg and a systolic blood pressure of 200 mm Hg or less.
Estimation of observed benefit of treatment. The observed incidence rates of coronary heart disease were compared in treated vs untreated hypertensive subjects who were identified on the basis of two consecutive biennial examinations. Treated subjects were defined as those who had a diastolic blood pressure of 95 mm Hg or higher and were not on treatment at a first examination, and who then reported taking antihypertensive medication and were free of all cardiovascular disease (coronary heart disease, cerebrovascular disease, or peripheral vascular disease) at the next examination. Untreated subjects had a diastolic blood pressure of 95 mm Hg or higher at a first examination, were free of cardiovascular disease at the next examination, and were not on treatment at either examination. For both treated and untreated hypertensive subjects, the incidence rate of coronary heart disease was calculated for the first 2 years at risk after the start of treatment or nontreatment, whichever occurred at the second examination. For patients who remained free of cardiovascular disease and whose treatment status remained unchanged after the first 2 years at risk, incidence rates were tabulated for the next 2 years, and so on, for up to four 2 year risk segments. Subjects who died during a 2 year risk period were included in the analysis and were included as incident cases of coronary heart disease if the cause of death was coronary heart disease.
Rates were stratified by systolic blood pressure at the first of the consecutive examinations, when all subjects were untreated. The association between antihypertensive treatment and the incidence of coronary heart disease was analyzed by multiple logistic regression analyses. Separate analyses were performed for the entire group of subjects, subjects within each blood pressure stratum, subjects in each risk segment, and subjects in each cell of the blood pressure-risk segment matrix. The analysis determined whether treatment of hypertension was correlated with the incidence of coronary heart disease after controlling for age, sex, serum cholesterol level, cigarette smoking, diabetes, and left ventricular hypertrophy at the examination at the start of each 2 year risk period. Systolic blood pressure was included in all analyses that contained subjects from more than one blood pressure stratum. If a logistic regression model contained subjects from more than one risk segment, a term for risk segment was included in the analysis. Age, cholesterol level, and systolic blood pressure were entered as continuous variables and the others as dichotomous variables. Left ventricular hypertrophy could not be included in three of the 12 cell-specific logistic regression models and diabetes could not be included in one of the 12 because of the small numbers of subjects within the cells who had these characteristics.
For each blood pressure stratum, the expected number of cases of coronary heart disease among treated subjects was calculated as the number that, when compared with the observed number of cases among treated subjects, would yield an odds ratio equivalent to that obtained from the logistic regression model. Changes in systolic blood pressures were calculated for treated and untreated subjects by subtracting the blood pressure reading at the initial examination from the reading taken at the start of the risk period. The difference in the mean blood pressure changes between treated and untreated subjects was defined as the net reduction in systolic blood pressure. An approximate power calculation was performed by assuming a normal distribution for the difference in two proportions whose denominators were identical to the total numbers of treated and untreated subjects in our data. Statistical analysis. Data linear trend). Treatment rates for women were 16% to 27% higher for diastolic hypertension (p < .001 at each examination) and 6% to 21% higher for systolic hypertension (p < .05 at each examination).
With sustained criteria, rates of treatment were also significantly higher at later examinations and in women (table 2) . Treatment rates based on sustained criteria were 12% to 20% higher than those based on crosssectional criteria.
Among treated hypertensive subjects, the rates of control increased significantly at later examinations (table 3) . When the experience of all six examinations was analyzed together, the difference in control rate between treated men and women was significant for systolic hypertension (p < .001) but not for diastolic hypertension (p > .1).
The distribution of diastolic blood pressure among subjects on treatment changed significantly between examinations 5 and 10 (p < .001; figure 1 ). At the fifth examination, between 1958 and 1960, 36% of those on treatment had diastolic blood pressures of 90 mm Hg or less, less than half had diastolic blood pressures of 95 mm Hg or less, and 21% had diastolic blood pressures of 101 mm Hg or greater. By the tenth examination, between 1968 and 1970, 70% of those on treat- Individuals in whom antihypertensive treatment was initiated were more likely to be female, were slightly older, and had higher blood pressures than hypertensive subjects who were not treated (table 4) . Treated subjects had a higher frequency of left ventricular hypertrophy, abnormal electrocardiogram, and cardiomegaly on the chest radiograph. The overall predicted risk of coronary heart disease was slightly higher in the treated group, reflecting greater age and higher blood pressure. The results were similar when the analysis was limited to subjects with diastolic blood pressure between 95 and 105 inm Hg, and also when criteria for sustained hypertension were used.
Stepwise multiple logistic regression analysis showed blood pressure, sex, age, the specific examination, and the presence of preexisting cardiovascular disease to be significant predictors of treatment (table   TABLE 3 Rates of control of hypertension 5 ). Analysis of each sex separately showed systolic blood pressure to be the only factor important for both. In the univariate analysis, older subjects were more likely to be treated. However, after controlling for blood pressure in the multivariate analysis, younger hypertensive subjects were more likely to be treated. Separate multivariate analyses of examinations 5 through 10 revealed no important differences in clinical factors influencing treatment at the various examinations.
Changes in cardiovascular risk factors associated with treatment. In cross-sectionally defined hypertensive subjects who were treated there was a mean reduction TABLE 5 of 13 mm Hg in systolic and 9 mm Hg in diastolic blood pressure, compared with small increases in untreated subjects (p < .0001; table 6). There was no significant difference between the two groups in change in mean serum cholesterol or blood glucose level, nor was the change in cigarette smoking significantly different between the two groups. Glucose intolerance increased more in the treated group than in the untreated group (p < .05), but the net difference was only 2% and mean blood glucose levels were no different. The predicted 8 year risk of coronary heart disease fell in the treatment group from 13.7% to 11.6%, a 15.3% reduction. Risk rose slightly in the untreated group, so the treatment group had a net predicted benefit of 2.3 coronary events per 100 people over 8 years (p < .0001). For men the net predicted difference was 2.9 coronary events and for women 2.2 coronary events per 100 people over 8 years. The difference in glucose intolerance between the treated and untreated groups was significant only among women (p < .05). Treated men stopped smoking cigarettes significantly more frequently than untreated men (p = .01).
Additional analysis of these two groups stratified by blood pressure at the earlier examination revealed no differences that were not apparent in the overall analysis. Changes in blood pressure were significantly different between treated and untreated groups only when the initial diastolic blood pressure was above 95 mm Hg or the initial systolic blood pressure was above 160 mm Hg. There were no significant differences between these two groups in change in mean cholesterol or glucose level at any stratum of systolic or diastolic blood pressure.
Comparison to treatment trial data. Reduction in blood pressure at 2 years in the ANBPS 13 14 was greater by 1 1 mm Hg systolic and 6 mm Hg diastolic in the treatment group than in the placebo group. In the comparable subset of the Framingham treatment group, the differences were 13 mm Hg systolic and 8 mm Hg diastolic. In the on-treatment analysis of the ANBPS, the treated group experienced 70 coronary heart disease end points in 5294 person-years, or 13.2 events per 1000 person-years, equivalent to a cumulative incidence of 10.0 events per 100 people over 8 years. In the placebo group there were 88 coronary heart disease end points in 5184 person-years, equivalent to 12.7 events per 100 people over 8 years. The difference, or reduction attributable to treatment, was 2.7 (95% confidence interval, -0.7 to + 6. 1) events per 100 people over 8 years. In the intent-to-treat analysis of the ANBPS, the treatment group experienced 10.6 coronary heart disease events and the placebo group had 11.9 coronary heart disease events per 100 people over 8 years, with a treatment effect of 1.3 (95% confidence interval, -1.6 to 4.2) coronary heart disease events per 100 people over 8 years.
Factors influencing selection of patients for treatment: multiple logistic regression analysis coefficients
Whereas data from the ANBPS describe observed rates of new events, the data from Framingham refer to predicted changes in coronary heart disease risk. In the subset of the Framingham cohort comparable to the subjects entered in the ANBPS, the treated group showed a predicted reduction of 1.2 events per 100 people over 8 years, while the untreated group showed a predicted increase of 0.4 events. The net predicted reduction attributable to treatment was 1.6 coronary heart disease events per 100 people over 8 years. Although the number is lower than the reduction observed in the on-treatment analysis of the ANBPS and greater than the reduction found in the intent-to-treat analysis, it is within the 95% confidence intervals of both.
Estimation of observed benefit of treatment in Framingham. When Framingham subjects with diastolic hypertension and all levels of initial systolic blood pressure were pooled, the treated and untreated groups had similar rates of coronary heart disease in years 1 and 2 (RR = 1.08, table 7) and in years 3 and 4 (RR = 1. 12). Event rates were only about one-half as high in treated subjects compared with those in untreated subjects in years 5 and 6 (RR = 0.43) and in years 7 and 8 (RR = 0. 54), but these differences were not statistically significant. Overall, treated subjects had a total of 33 incident events compared with an expected 39.16 events based on their risk factors and the event rates of the untreated subjects. This 15.7% reduction in observed incidence was similar to our predicted 15.3% reduction in treated patients, to the predicted 16.8% net benefit (2.3/13.7) when the worsening risk factor status in untreated hypertensive subjects was taken into account, and to the observed benefit in the ANBPS data. Although the reduction in observed incidence was not statistically significant, a comparison of two populations whose denominators were identical to our sample size would have only a 10% power for detecting statistical significance if treatment truly reduces incidence by 15.3%. The apparent benefits of treatment were found only in the highest stratum of pretreatment blood pressure. Logistic regression analysis among subjects with systolic blood pressures of 180 mm Hg or greater showed that treated subjects had approximately half the incidence rate of coronary heart disease as untreated subjects both before and after controlling for differences in other cardiac risk factors (p = .04). This overall difference was concentrated in years 3 to 8, when untreated subjects with initial systolic blood pressures of 180 mm Hg or greater had over twice the incidence rates found either in treated patients with pretreatment systolic blood pressures of 180 mm Hg or greater or in untreated patients with lower systolic blood pressures. The reduced incidence of observed coronary heart disease in years 3 to 8 in subjects with initial systolic blood pressures of 180 mm Hg or greater was associated with a net reduction in systolic blood pressure of 13.3 to 16.9 mm Hg. In subgroups where incidence rates were not lower in treated patients, net reductions in blood pressure were more modest or were not observed. ANumerators refer to incident cases of coronary heart disease and denominators to subjects at risk during a given time segment.
Discussion
Values in parentheses are percent.
BBased on pretreatment systolic blood pressure (see Methods). jects show substantial improvement in the treatment and control of hypertension in the medical practice of one community during the period from 1958 to 1970. Estimates of the prevalence of untreated hypertension were substantially lower when sustained rather than cross-sectional criteria were used to define the presence of hypertension.
Rates of treatment and control were almost certainly higher in Framingham during this period than in the United States as a whole. For example, the Hypertension Detection and Follow-up Program' screened 158,906 men and women in 1973 and 1974 and found that 54% of hypertensive subjects were on treatment, significantly less than the 69% of the cross-sectionally defined hypertensive subjects in Framingham who were on treatment at the tenth examination in 1968 to 1970. Similarly, a recent report7 indicated that in 1973 to 1974 in Minneapolis-St. Paul, approximately 43% of men and 67% of women with hypertension, defined by criteria similar to our cross-sectional criteria, were on treatment, compared with 52% of men and 79% of women in Framingham at the tenth examination. These comparisons must be interpreted with caution because the rates are age-standardized to different reference populations, but they suggest that rates of treatment and control of hypertension were higher in Framingham during this period than in most other communities in the United States. These higher rates of treatment and control may reflect social, economic, and racial differences between the populations studied, selection factors related to participation in the Framingham Study, or a more aggressive approach to hypertension treatment by practitioners at Framingham. The data we report do not describe treatment practices for isolated systolic hypertension.
Compared with untreated Framingham hypertensive subjects, treated hypertensive subjects had higher systolic and diastolic blood pressures, were slightly older, and were more likely to have preexisting cardiovascular disease and to be women. Since not all patients told by their physicians to take medicines actually do so, these data do not directly reflect decisions by physicians about which hypertensive subjects to treat, but they do suggest that other risk factors such as cigarette smoking, serum cholesterol level, and glucose intolerance had little influence on this decision. The higher rate of treatment among women cannot be explained by higher blood pressure, higher levels of other risk factors, or greater frequency of preexisting cardiovascular disease. It is possible that women were treated more frequently because they went to doctors more often or were more willing to take medicine than men.
Subjects who were treated with antihypertensive drugs experienced significant reductions in systolic and diastolic blood pressure without suffering increases in serum cholesterol or glucose levels. A number of short-term studies have demonstrated that thiazide diuretics may be associated with elevations in serum cholesterol level in the range of 5 to 15 mg/dl. '1 -21 There are several possible reasons why we did not find evidence of this effect in our study population. First, the interval between examinations at Framingham was 2 years, considerably longer than the observation period in most studies of the metabolic effects of diuretics. Second, the dosage may have been lower in our population. Third, some of our subjects may have been treated with antihypertensive agents not associated with these metabolic effects, particularly rauwolfia alkaloids. Although we do not have data regarding dose or specific antihypertensive agents taken by our subjects, thiazide diuretics were in wide use as firstline drugs for treatment of hypertension during the period of these observations. Fourth, compliance with medication regimen in our population may not have been as complete as in more closely monitored shortterm metabolic studies, although the substantial reduction of blood pressure in the treated group suggests that compliance was reasonable.
Antihypertensive treatment was associated with a 2% net increase in glucose intolerance between the treated and untreated groups, although changes in mean blood glucose in the two groups were not significantly different. While glucose intolerance is a more important predictor of cardiovascular risk than changes in serum glucose level within the normal range,22 our calculated reduction in coronary heart disease risk associated with antihypertensive treatment, based on the seven-factor multiple logistic regression model, took this small increase in glucose intolerance into account.
Observational data from a nonrandomized cohort study cannot answer definitively whether the treatment of hypertension reduces coronary heart disease mortality or event rates, and a far larger sample size would be required even if one were to try to use observational data to settle this issue. However, our data are consistent with the hypothesis that the treatment of hypertension contributed to the national downturn in coronary Vol. 71, No. 1, January 1985 heart disease mortality. The predicted reduction of coronary heart disease events based on the Framingham equations was similar to the observed reduction in subjects randomized to "intention to treat" in the ANBPS. '2, 13 In addition, our results suggest that when pretreatment systolic blood pressure was 180 mm Hg or greater, treatment for more than 2 years was associated with substantial average net reductions in systolic blood pressure and a lower incidence of coronary heart disease. The lack of observed benefit of treatment overall or in subgroups of subjects with lower systolic blood pressure does not disprove the predicted benefit from treatment because of our inadequate sample size. In fact, the overall 15.7% observed reduction in incident events was similar to the predicted 15.3% to 16.8% reduction based on risk factor reductions and to the observed benefit reported by the ANBPS.
